Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Accumulated Expenses (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Other Accumulated Expenses for 9 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 27.34% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 27.34% year-over-year, with the annual reading at $2.9 million for FY2025, 27.34% down from the prior year.
  • Other Accumulated Expenses hit $2.9 million in Q4 2025 for Sutro Biopharma, down from $15.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $17.8 million in Q2 2025 to a low of $185000.0 in Q1 2021.
  • Historically, Other Accumulated Expenses has averaged $5.0 million across 5 years, with a median of $3.4 million in 2024.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 91.39% in 2021 and later skyrocketed 1408.11% in 2022.
  • Year by year, Other Accumulated Expenses stood at $2.8 million in 2021, then grew by 12.0% to $3.1 million in 2022, then grew by 26.53% to $3.9 million in 2023, then grew by 2.87% to $4.0 million in 2024, then fell by 27.34% to $2.9 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for STRO at $2.9 million in Q4 2025, $15.8 million in Q3 2025, and $17.8 million in Q2 2025.